HOP's Inherited Genetic Cancer Risk Screening paused as of May 2025. Participants who activated and returned their saliva sample by May 31, 2025, can expect to receive results as explained in the consent process.
The genetic screening included the following genes, which are associated with inherited cancer syndromes and increased cardiology risk:
| APC |
BRIP1 |
MITF |
PMS2 |
RET |
TP53 |
| ATM |
CDH1 |
MLH1 |
POLD1 |
SDHB |
TSC1 |
| BAP1 |
CDK4 |
MSH2 |
PTEN |
SDHC |
TSC2 |
| BMPR1A |
CDKN2A |
MSH6 |
RAD51C |
SDHD |
VHL |
| BRCA1 |
LDLR |
MUTYH |
RAD51D |
SMAD4 |
|
| BRCA2 |
MEN1 |
PALB2 |
RB1 |
STK11 |
|
Medical guidelines may change over time as our understanding of genetics evolves. We only report gene changes that have established medical guidelines that could impact your clinical care. The result you are given will be based on the current medical guidelines at the time your report is issued.